PALO ALTO — The capital markets have long been challenging for young biotech companies, with revenues still years off and innovations that play out in laboratories and operating rooms—not in the palm of one’s hand.

But as the end of the year looms, the biotech IPO market is booming, reviving the life sciences ecosystem and auguring unprecedented options for companies taking root there.